Mereo BioPharma Group plc
MREO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $10,000 | $0 | $49,213 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | $0 | $2,574 | -$257 | $24,169 |
| Gross Profit | $0 | $7,426 | $257 | $25,044 |
| % Margin | – | 74.3% | – | 50.9% |
| R&D Expenses | $20,930 | $17,418 | $30,748 | $31,796 |
| G&A Expenses | $26,434 | $18,424 | $0 | $21,504 |
| SG&A Expenses | $26,434 | $18,424 | $23,177 | $21,504 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $47,364 | $35,842 | $53,925 | $53,300 |
| Operating Income | -$47,364 | -$28,416 | -$53,667 | -$28,256 |
| % Margin | – | -284.2% | – | -57.4% |
| Other Income/Exp. Net | $4,111 | -$1,582 | $9,209 | $47,476 |
| Pre-Tax Income | -$43,253 | -$29,998 | -$44,459 | $19,220 |
| Tax Expense | $0 | -$532 | -$2,337 | $2,046 |
| Net Income | -$43,253 | -$29,466 | -$42,122 | $17,174 |
| % Margin | – | -294.7% | – | 34.9% |
| EPS | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| % Growth | 100% | 37.1% | -333.5% | – |
| EPS Diluted | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| Weighted Avg Shares Out | 147,925 | 131,891 | 120,640 | 116,734 |
| Weighted Avg Shares Out Dil | 147,925 | 131,891 | 120,639 | 116,734 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,042 | $2,131 | $696 | $1 |
| Interest Expense | $1,371 | $2,881 | $3,361 | $5,222 |
| Depreciation & Amortization | $1,088 | $1,061 | $896 | $866 |
| EBITDA | -$40,795 | -$26,056 | -$39,979 | $25,487 |
| % Margin | – | -260.6% | – | 51.8% |